Syn-Ake vs Larazotide Acetate
Side-by-side comparison of key properties, dosing, and research.
Skin & CosmeticAnti-Aging & Longevity
Syn-AkeRecovery & Repair
Larazotide Acetate- Summary
- Syn-Ake is a synthetic tripeptide that mimics waglerin-1, a peptide found in the venom of the Temple viper (Tropidolaemus wagleri). It acts as a reversible antagonist of muscular nicotinic acetylcholine receptors, temporarily reducing facial muscle contraction and smoothing dynamic wrinkles. Often called a 'synthetic Botox' in cosmetic marketing.
- Larazotide acetate is an 8-amino acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) derived from Zonula Occludens Toxin (ZOT) of Vibrio cholerae. It paradoxically acts as a ZOT antagonist to close tight junctions and reduce intestinal permeability ('leaky gut'). It is the most advanced clinical compound targeting gut permeability directly.
- Half-Life
- Not applicable (topical; effect duration hours)
- Local gut action; minimal systemic exposure
- Admin Route
- Topical
- Oral
- Research
- —
- —
- Typical Dose
- 0.01–0.1% (4–8 mg/g in clinical studies)
- 0.5-2 mg
- Frequency
- Twice daily
- 3x daily
- Key Benefits
- Reduces depth of dynamic wrinkles and expression lines
- Reversible muscle-relaxing effect on facial muscles
- Smooths forehead lines, crow's feet, and frown lines
- Non-invasive alternative to injectable neurotoxins
- Rapid onset relative to collagen-stimulating peptides
- Well-studied in in vitro and clinical cosmetic trials
- Directly reduces intestinal tight junction permeability
- Clinical efficacy in celiac disease (Phase 3 trials)
- Reduces systemic inflammation from gut permeability
- Targets root cause of leaky gut (Zonulin pathway)
- Local gut action without systemic absorption
- Potential application in IBS, IBD, autoimmune conditions
- Side Effects
- Generally very well-tolerated topically
- Rare skin sensitivity or contact dermatitis
- Theoretical neuromuscular effects at systemic doses (not relevant topically)
- Headache (mild, dose-dependent)
- Nausea (rare)
- Well-tolerated overall in clinical trials
- Stacks With
- —
- —